Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Rad to Sell $300M in Senior Notes

NEW YORK (GenomeWeb News) – Bio-Rad Laboratories said today that it will raise $300 million through the sale of senior notes through a private offering.

The $300 million, which the company plans to use for general corporate purposes, working capital, and potentially for acquisitions, is an increase of $50 million over what the company said on Monday that it planned to receive from the sale.

Under the agreement, it will sell $300 million in aggregate principal of the 8 percent subordinated senior notes, which will be due in 2016.

Bio-Rad said that the notes "may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act and applicable state securities laws."

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.